Use the Search Fields to Find Information
Page 55 of 373
The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets
Abstract Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety,
April 24, 2024
The (endo)cannabinoid signaling in female reproduction: What are the latest advances?
Please use this link to access this publication. Abstract Cannabis extracts like marijuana have the highest consumption rate worldwide. Yet, their societal acceptance as recreational
August 30, 2025
The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders
Abstract Mood disorders are the most prevalent mental conditions encountered in psychiatric practice. Numerous patients suffering from mood disorders present with treatment-resistant forms of depression,
November 22, 2023
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms
Background: The prospective observational MObility ImproVEment (MOVE) 2 study is collecting real-life clinical outcomes data on patients with treatment-resistant multiple sclerosis (MS) spasticity treated with
September 19, 2019
THC:CBD in Daily Practice: Available Data from UK, Germany and Spain
Abstract Background: From the time Sativex (THC:CBD) oromucosal spray first became available in European Union countries in 2010 for the management of treatment-resistant multiple sclerosis (MS)
September 4, 2024
THC Regulates Tearing via Cannabinoid CB1 Receptors
Abstract Purpose: Aqueous deficiency dry eye (ADDE) is a chronic condition affecting millions, with symptoms ranging from a dry itchiness to blurred vision and accompanied by
May 31, 2024
THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner
Abstract Glioblastoma (GBM) is the most frequent malignant tumor of the central nervous system in humans with a median survival time of less than 15
April 30, 2024
THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation
Please use this link to access this publication: https://www.sciencedirect.com/science/article/abs/pii/S0165178123005930 Abstract Prenatal infections and cannabis use during adolescence are well-recognized risk factors for schizophrenia. As inflammation and
December 6, 2023
THC Exposure is Reflected in the Microstructure of the Cerebral Cortex and Amygdala of Young Adults
Abstract The endocannabinoid system serves a critical role in homeostatic regulation through its influence on processes underlying appetite, pain, reward, and stress, and cannabis has
May 31, 2024
THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia
Please use this link to access this publication. Abstract Cannabis use has been associated with an increased risk to develop schizophrenia as well as symptom
September 4, 2024
Page 55 of 373